Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging

Janina Krell-Roesch, Maria Vassilaki, Michelle M Mielke, Walter K Kremers, Val Lowe, Prashanthi D Vemuri, Mary Margaret Machulda, Teresa J. Christianson, Jeremy A. Syrjanen, Gorazd B. Stokin, Lesley M. Butler, Martin Traber, Clifford R Jr. Jack, David S Knopman, Rosebud O Roberts, Ronald Carl Petersen, Yonas Endale Geda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11 C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms.

Original languageEnglish (US)
Article number123
JournalTranslational psychiatry
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Neurobehavioral Manifestations
Amyloid
Equipment and Supplies
Anxiety
Cognitive Dysfunction
Depression
Symptom Assessment
Sex Education
Psychiatry
Alzheimer Disease
Cross-Sectional Studies
Logistic Models
Odds Ratio
Genotype
Regression Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Biological Psychiatry

Cite this

Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status : the Mayo Clinic Study of Aging. / Krell-Roesch, Janina; Vassilaki, Maria; Mielke, Michelle M; Kremers, Walter K; Lowe, Val; Vemuri, Prashanthi D; Machulda, Mary Margaret; Christianson, Teresa J.; Syrjanen, Jeremy A.; Stokin, Gorazd B.; Butler, Lesley M.; Traber, Martin; Jack, Clifford R Jr.; Knopman, David S; Roberts, Rosebud O; Petersen, Ronald Carl; Geda, Yonas Endale.

In: Translational psychiatry, Vol. 9, No. 1, 123, 01.12.2019.

Research output: Contribution to journalArticle

@article{8d5c42cb4b10413bb98c923bd2f0591b,
title = "Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging",
abstract = "Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54{\%} males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11 C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms.",
author = "Janina Krell-Roesch and Maria Vassilaki and Mielke, {Michelle M} and Kremers, {Walter K} and Val Lowe and Vemuri, {Prashanthi D} and Machulda, {Mary Margaret} and Christianson, {Teresa J.} and Syrjanen, {Jeremy A.} and Stokin, {Gorazd B.} and Butler, {Lesley M.} and Martin Traber and Jack, {Clifford R Jr.} and Knopman, {David S} and Roberts, {Rosebud O} and Petersen, {Ronald Carl} and Geda, {Yonas Endale}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41398-019-0456-z",
language = "English (US)",
volume = "9",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status

T2 - the Mayo Clinic Study of Aging

AU - Krell-Roesch, Janina

AU - Vassilaki, Maria

AU - Mielke, Michelle M

AU - Kremers, Walter K

AU - Lowe, Val

AU - Vemuri, Prashanthi D

AU - Machulda, Mary Margaret

AU - Christianson, Teresa J.

AU - Syrjanen, Jeremy A.

AU - Stokin, Gorazd B.

AU - Butler, Lesley M.

AU - Traber, Martin

AU - Jack, Clifford R Jr.

AU - Knopman, David S

AU - Roberts, Rosebud O

AU - Petersen, Ronald Carl

AU - Geda, Yonas Endale

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11 C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms.

AB - Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11 C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms.

UR - http://www.scopus.com/inward/record.url?scp=85063624858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063624858&partnerID=8YFLogxK

U2 - 10.1038/s41398-019-0456-z

DO - 10.1038/s41398-019-0456-z

M3 - Article

C2 - 30923322

AN - SCOPUS:85063624858

VL - 9

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 1

M1 - 123

ER -